Duquesne University of the Holy Spirit

Other

Paula A Witt-Enderby

Vicki L Davis

Kenneth A McGowan

Ellen S Gawalt

James Louis Rutkowski

Rachelle Palchesko

David Lapinsky

James Rutkowski

David J Lapinsky

Kenneth Mcgowan

A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.

Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer

A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxytamoxifen and also melatonin, with the tamoxifen or 4-hydroxytamoxifen and melatonin's being linked by an unsubstituted C-Calkyl linker between the tamoxifen amine and the carbonyl of melatonin.

Anti-cancer tamoxifen-melatonin hybrid ligand

A bone implant, and bone implant material, includes a calcium- and oxide-containing artificial graft material in a scaffold, to which melatonin and an optional cell adhesion peptide are absorbed or covalently linked.

Bone implant

Growing community of inventors

Bethel Park, PA, United States of America

Paula A Witt-Enderby